表达“免疫原性细胞死亡”(ICD)是指细胞死亡的功能独特形式,其促进(而不是抑制)对死细胞衍生的抗原具有特异性的T细胞依赖性免疫应答。ICD主要依赖于死亡细胞中适应性反应的激活,以通常称为“损伤相关分子模式”的免疫刺激分子的暴露或分泌结束。只有少数特工可以引发真正的ICD,包括一些临床上确定的化疗药物,如阿霉素,表柔比星,伊达比星,米托蒽醌,博来霉素,硼替佐米,环磷酰胺和奥沙利铂。在这个审判观察中,我们讨论了ICD诱导化疗方案的最新进展,专注于与免疫学生物标志物结合评估临床疗效的研究。
The expression \"immunogenic cell death\" (ICD) refers to a functionally unique form of cell death that facilitates (instead of suppressing) a T cell-dependent immune response specific for dead cell-derived antigens. ICD critically relies on the activation of adaptive responses in dying cells, culminating with the exposure or secretion of immunostimulatory molecules commonly referred to as \"damage-associated molecular patterns\". Only a few agents can elicit bona fide ICD, including some clinically established chemotherapeutics such as doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin. In this
Trial Watch, we discuss recent progress on the development of ICD-inducing chemotherapeutic regimens, focusing on studies that evaluate clinical efficacy in conjunction with immunological biomarkers.